Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Arsenic Trioxide (AAA) in Newly Diagnosed APL
NCT04687176Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute promyelocytic leukemia (APL), sponsored by The University of Hong Kong. Primary endpoints: Relapse-free survival at 60 months and Event-free survival at 60 months. Started Jan 2021; status: recruiting.
02
Drugs
arsenic trioxide
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT04687176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687176.